During the last five years there has been interest in developing non-cytotoxic, targeted @entity5 treatments. This phenomenon has occurred as a result of increased information regarding factors which regulate @entity5 proliferation, survival, angiogenesis, invasiveness, and metastatic potential. In @entity1149 many investigators have focused their attention on the @entity470 ( @entity470 ) because this membrane protein, which has an extracellular ligand binding domain, as well as, @entity669 kinase activity on the intracellular portion of the molecule, is expressed in a relatively high proportion of @entity1149 . @entity4562 which was the first @entity470 specific @entity669 kinase inhibitor to be extensively tested in @entity1149 has shown single agent activity in @entity1149 . Subsequently, @entity3866 , another @entity470 specific @entity669 inhibitor, has also demonstrated single agent activity in @entity1149 . Phase III trials of @entity3866 alone or in combination with chemotherapy have been completed, and data are being analyzed. Several dual inhibitors of erb B1 and erb B2 ( @entity26501 , @entity9433 , @entity69166 ) have been or are being tested in phase I trials. In addition, CI 1033, a pan-erb inhibitor, is also being tested in phase I studies. @entity294 and @entity1910 have been the predominant side effects of these agents. Life threatening @entity137 has been rare. Although the erb @entity669 kinase inhibitors are attrative agents to use in treating @entity1149 because of their relatively benign @entity137 profile, more data are needed to define the role of these agents in @entity1149 .

Clinical studies with non-iressa XXXX @entity669 kinase inhibitors.

@entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity'] @entity4562 :: ('MESH:C419708', 'Chemical') :: ['Gefitinib'] @entity1910 :: ('MESH:D005076', 'Disease') :: ['rash'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'cancer'] @entity470 :: ('1956', 'Gene') :: ['EGFR', 'epidermal growth factor receptor'] @entity26501 :: ('MESH:C410026', 'Chemical') :: ['PKI 166'] @entity1149 :: ('MESH:D002289', 'Disease') :: ['non-small cell lung cancer', 'non-small cell lung cancers'] @entity9433 :: ('MESH:C490728', 'Chemical') :: ['GW 572016'] @entity69166 :: ('MESH:C413879', 'Chemical') :: ['EKB 569'] @entity294 :: ('MESH:D003967', 'Disease') :: ['Diarrhea'] @entity669 :: ('CHEBI:18186', 'Chemical') :: ['tyrosine'] @entity3866 :: ('MESH:C400278', 'Chemical') :: ['erlotinib']
@entity470 :: (1956,Gene) :: ['EGFR']
